Healthy Volunteers Clinical Trial
Official title:
A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers.
NCT number | NCT01117142 |
Other study ID # | 100097 |
Secondary ID | 10-H-0097 |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 3, 2010 |
Est. completion date | July 10, 2020 |
Verified date | July 2020 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell
lymphoma (MCL) are types of cancers in which there are too many abnormal lymphocytes (a
type of white blood cell). Monoclonal B-cell lymphocytosis (MBL) is a condition in which
the individual has a larger than normal number of lymphocytes. Individuals with CLL,
SLL, MBL, and MCL may survive for many years without the need for treatment, but there
is an apparent correlation between cell birth rates and disease activity. By studying
the birth and death rates of lymphocytes, researchers hope to identify individuals who
are at risk for worsening disease.
- Heavy water is similar in structure to regular water, but it has two deuterium atoms
instead of two hydrogen atoms. Deuterium has one more neutron than hydrogen, which is
what makes heavy water heavy. Heavy water is not radioactive, looks and tastes like
regular water, and has no known harmful effects at research-level doses. When a small
amount of heavy water is consumed daily, newly produced blood cells are labeled
(tagged), which allows researchers to track cell growth and to measure the birth and
death rates of CLL, SLL, MBL, MCL or normal lymphocytes.
Objectives:
- To study the birth and death rates of lymphocytes from individuals with MBL, CLL/SLL, and
MCL, compared with lymphocytes from healthy volunteers.
Eligibility:
- Individuals at least 18 years of age who have been diagnosed with MBL, CLL, SLL, or MCL,
but who have not been taking certain agents (Viagra, Levitra, Cialis, or other
PDE-inhibitors, prednisone, cyclosporin-A, rapamycin, or other immunosuppressive agents,
more than 2 cups of green tea daily, or Celebrex) for 4 weeks prior to enrollment in the
study.
- Healthy volunteers at least 18 years of age, but who have not been taking certain agents
(Viagra, Levitra, Cialis, or other PDE-inhibitors, prednisone, cyclosporin-A, rapamycin,
or other immunosuppressive agents, more than 2 cups of green tea daily, or Celebrex)for
4 weeks prior to enrollment in the study.
Design:
- Participants will be screened with a medical history, physical examination, and initial
blood tests. Other tests may be administered to the individuals with cancer, as required
by the study researchers.
- All participants will drink regular doses of heavy water daily for a total of 4 weeks
(labeling period). There is an optional 6-month follow-up or wash-out period during
which no additional heavy water will be consumed.
- Blood samples will be collected weekly during the labeling period, and a bone marrow
biopsy will be obtained where possible. Individuals with cancer may also have a lymph
node biopsy during this part of the study.
- Additional blood samples may be collected during the optional wash-out phase of the
study to determine the rate at which cancer cells disappear.
- Treatment is not provided as part of this protocol.
Status | Completed |
Enrollment | 20 |
Est. completion date | July 10, 2020 |
Est. primary completion date | July 10, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
- INCLUSION CRITERIA: (MBL, CLL/SLL, MCL group) 4.1.1.<TAB>Diagnosed with MBL, CLL/SLL, or MCL 4.1.2.<TAB>Greater than or equal to 18 years of age 4.1.3.<TAB>Neutrophil count (ANC) greater than or equal to 1000/mcL 4.1.4.<TAB>Platelet count greater than or equal to 50K/mcL EXCLUSION CRITERIA: (MBL, CLL/SLL, MCL group) 4.2.1.<TAB>Concomitant use of agents that have been described to affect the biology and/or proliferation rate of CLL cells but are not approved or accepted therapies for CLL, SLL, MCL, or MBL - PDE-inhibitors (e.g. sildenafil, theophylline) - Immunosuppressive agents (e.g., prednisone, cyclosporin-A, rapamycin) - Green Tea extract (more than 2 cups per day) - Cox-2 inhibitors 4.2.2.<TAB>Chronic or current clinically significant infection, including HIV or uncontrolled infection 4.2.3.<TAB>Receiving concurrent anticancer therapies 4.2.4.<TAB>Women who are pregnant or nursing, as well as women of childbearing potential who are unwilling to use a an agreed upon form of contraception for the duration of participation in this study 4.2.5<TAB>Sexually active males who are unwilling to follow the strict contraception requirements described in this protocol. 4.2.6<TAB>Inability to understand the investigational nature of the study, inability to provide informed consent INCLUSION CRITERIA: (Healthy volunteer group) 4.3.1<TAB>Health status will be confirmed by brief History and Physical Exam and blood work 4.3.2<TAB>Greater than or equal to 18 years of age 4.3.3<TAB>CBC and coagulation panel within the expected normal ranges for the subject EXCLUSION CRITERIA: (Healthy volunteer group) 4.4.1.<TAB>Concomitant use of agents that have been described to affect the biology and/or proliferation rate of CLL cells - PDE-inhibitors (e.g. , slidenafil, theophylline) - Immunosuppressive agents (e.g., cyclosporin-A, rapamycin) - Green Tea extract (more than 2 cups per day) - Cox-2 inhibitors <TAB> 4.4.2.<TAB>Women who are pregnant or nursing, as well as women of childbearing potential who are unwilling to use an agreed upon form of contraception for the duration of study participation. 4.4.3<TAB> Sexually active males who are unwilling to follow the strict contraception requirements described in this protocol. 4.4.4.<TAB>Inability to understand the investigational nature of the study, inability to provide informed consent |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Heart, Lung, and Blood Institute (NHLBI) | Northwell Health |
United States,
Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998 Jan 1;91(1):3-21. Review. — View Citation
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27. — View Citation
Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur J Cancer Care (Engl). 2005 Mar;14(1):53-62. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint is the estimate of the cell proliferation rate of tumor cells in individuals with MBL, CLL/SLL, and MCL | Cell proliferation rate of tumor cells | 28 days | |
Secondary | Secondary endpoints include: Proliferation rate in tissue compared to blood, disappearance rate of labeled cells from the blood and tissue and the safety profile of heavy water in the study population/ | 28 to 196 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |